menu
    • menu
    [{"orgOrder":0,"company":"Amzell B.V","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"NETHERLANDS","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Diclofenac Sodium","moa":"Cyclooxygenase","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"Amzell B.V","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Gel","sponsorNew":"Amzell B.V \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Amzell B.V \/ Undisclosed"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Argenx

                            Netherlands arrow
                            FNCE
                            Not Confirmed

                            Argenx

                            Netherlands arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Efgartigimod

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiop...

                            Details : Efgartigimod is a Antibody drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Myositis.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            August 31, 2022

                            Lead Product(s) : Efgartigimod

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Amzell B.V

                            Netherlands arrow
                            FNCE
                            Not Confirmed

                            Amzell B.V

                            Netherlands arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Diclofenac Sodium

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 2/3 Trial Suggests that Amzell’s New Topical Treatment (AMZ001) for the Treatment of Knee Osteoarthrit...

                            Details : This phase 2/3 multi-center, randomized, double-blind trial investigated the effect of a new 3.06% diclofenac sodium gel formulation (AMZ001) for the relief of knee OA pain, in 444 patients exposed to either AMZ001 once daily (QD), AMZ001 twice daily (BI...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 14, 2020

                            Lead Product(s) : Diclofenac Sodium

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth